What Is Drugs Made In America Acquisiti (DMAA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Drugs Made In America Acquisiti's intrinsic value is estimated at $3.13, suggesting the stock is overvalued at its current price of $10.67. With 10 out of 11 models flagging downside (-70.7% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: Regime Cross targets $11.21 (+5.0%), versus PWERM at $0.76 (-92.8%). This +97.9% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About DMAA?
11 of 13 models are currently active for DMAA. Of these, 1 model suggests upside while 10 models suggest overvaluation. The Bayesian DCF estimates DMAA's intrinsic value at $0.87, implying -91.8% downside from the current price. See which stocks rank higher →
How Does DMAA Rank in Blank Checks?
Among 206 Blank Checks stocks, DMAA ranks #10 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.
See all Most Undervalued Blank Checks Stocks →
Drugs Made In America Acquisiti operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is DMAA a Value Trap?
The Value Trap algorithm is not active for DMAA. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Drugs Made In America Acquisiti. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Drugs Made In America Acquisiti is rated at 5.6/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +97.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every DMAA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across DMAA's 11 active models, average confidence is 23%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad